| ||||||
clinical trials |
||||||
NEWS, PUBLICATIONS, AND RELATED STORIES  Mouse study shows dopamine blocks tumor-feeding blood vessels "Sometimes new drugs may not be the answer. We looked instead at a novel use for an established product and have found very promising results," says Mayo Clinic oncology researcher Sujit Basu, M.D., Ph.D. Agreement strengthens relationship and spawns new scientific collaborations "TGen takes seriously our commitment to work toward helping patients with cancer and other disorders. This announcement is another mechanism allowing TGen and Mayo faculty to work bi-directionally in a more seamless fashion," said Jeffrey Trent, Ph.D., TGen's president and scientific director. View Related  Research into the B7 molecules has been a "family affair" at Mayo. Many Mayo immunologists have joined together to tackle various aspects of their function and behavior and have discovered how they function. View Related   Presented at the annual meeting of the American Society for Therapeutic Radiation and Oncology (ASTRO) "Most of these patients don't have other effective treatment options, because surgery is not possible if there are multiple tumors in their liver," says the study's lead investigator, Laura Vallow, M.D. "But with this radiotherapy, no new tumors developed in patients who responded and we find this to be very encouraging." View Related     Until now there were no strongly-predictive molecules for prostate cancer. "This discovery will allow physicians to individualize treatment and observation plans for prostate cancer patients," says Timothy Roth, M.D., a Mayo Clinic urology resident and lead author of the study. "Being able to tell a patient his specific risk after surgery, and perhaps even prior to surgery, will be a huge step forward." View Abstract Two Mayo Clinic Cancer Center Researchers Receive Honor Named professorships at Mayo Clinic represent the highest academic distinction for a faculty member. Faculty is appointed to a professorship through nomination and endorsement of their peers and then confirmed by Mayo Clinic senior leadership. Appointed individuals are recognized for distinguished achievement in their specialty areas and for service to the institution. View Related     Mayo Clinic Cancer Center had researchers from many disciplines presenting more than 60 oral abstracts and dozens of posters, also educational sessions and other special events throughout the 2007 ASCO program, June 1-5. View Related  The National Institutes of Health chose Mayo Clinic as one of the first 12 institutions to receive Clinical and Translational Science Awards (CTSA) in October 2006. "There are two objects in medical education: to heal the sick and advance the science." - Dr. Charles H. Mayo View Related  Yuan-Ping Pang, Ph.D. established the Computer-Aided Molecular Design Laboratory (CAMDL) to learn more about how biological systems function and to establish models that could lead to new treatments for infectious diseases and cancer. View Related  Special Event: June 3, 2007 -- Rochester, Minn. "This celebration of life is for everyone," says Janine Kokal, local planning committee chair and a Mayo Clinic nurse educator. This is a free event, but reservations are required by May 28, 2007. To register, call the American Cancer Society at 507-424-4602 or 1-888-535-4227 (toll free). View Related  Osteoporosis was not even considered a disease before Mayo Clinic's 1980s groundbreaking epidemiology studies. Funded by a $1.2 million per year NIH Program Project grant, the osteoporosis research team is also taking their research to the genetic and molecular levels to study the physiology of bone metabolism in an aging population. Their studies investigate the TGF-beta-Inducible Early Gene (TIEG) gene's role in bone and skeletal disorders such as osteoporosis and breast cancer metastasis to the bone. View Related  Special Event: April 28, 2007, Rochester, Minn. Understanding the health risks and becoming educated about the issues surrounding prostate cancer can empower individuals to make decisions that may affect their quality of life and the potential outcome of the disease. View Related   From studies reviewing basic laboratory science, to clinical trials and the final translation of that research to individualized patient care, Mayo Clinic Cancer Center has a broad portfolio of presentations at the 2007 AACR meeting. View Related  Patients with a PSA doubling time of less than three months after therapy are at imminent risk of death from prostate cancer. View Abstract  $8.5 million for Alzheimer's, cancer research and more The Minnesota Partnership for Biotechnology and Medical Genomics is a unique collaborative venture among the Mayo Clinic, University of Minnesota and State of Minnesota. The Partnership seeks to position Minnesota as a world leader in biotechnology and medical genomics applications that will result in important new medical discoveries, thereby improving health care for patients and supporting the development of new business and jobs in Minnesota. View Related  Medical Edge Newspaper Readers: A cancer diagnosis is frightening. But the number of cancer survivors continues to grow, thanks to new and improved treatments and earlier diagnosis. More than 10 million Americans with a history of cancer were alive in January 2002. One in every six people over age 65 has survived cancer. It's encouraging to look at the progress... View Related   Intent on incorporating the patient's voice into cancer research and care, Mayo Clinic Cancer Center investigators have sought out the best practices, promising techniques and novel applications for quality of life (QOL) assessment. "We expect that QOL assessments will someday become as routine as having your blood pressure checked," says Dr. Jeff Sloan. "After all, if the best interests of the patient are what we seek, incorporating their needs into regular care is imperative." View Abstract  Mayo Clinic Cancer Center Finds Age Not Automatic Barrier to Men with Prostate Cancer "Increased life expectancy and generally higher levels of wellness, as well as safer forms of anesthesia and less-invasive surgical techniques, have made it possible for older adults to safely and effectively have surgeries traditionally not offered over a certain age," says Michael Lieber, M.D., Mayo Clinic urologist and the study's senior investigator. View Abstract  Mayo Clinic Cancer Center's Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) for prostate cancer research has been renewed for an additional five years. SPORE grants are highly competitive awards given to institutions on the cutting edge of translational research in specific types of cancer. View Related  More than 200 clinicians and researchers attended the 2nd Mayo Clinic Angiogenesis Symposium, Oct. 27-29, 2006. Angiogenesis is the specific growth of new blood vessels to accommodate tumor growth and the spread of many cancers. View Related  Mayo Clinic Cancer Center researchers see CDK2/FOXO1 as drug target Mayo Clinic researchers have found that a protein that initiates a "quality control check" during cell division also directs cell death for those cells damaged during duplication. This knowledge represents a potential "bulls eye" for targeting anti-tumor drugs. View Abstract  Mayo Awarded $72 Million for Clinical and Translational Research "The Mayo Clinic Center for Clinical and Translational Research will coordinate the efforts of our outstanding clinical research education and training programs, our world-class scientists and clinical research investigators, and the vast resources of Mayo Clinic to speed the process of turning our research discoveries into the medications and treatments our patients need and expect," says Robert Rizza, M.D., Mayo Clinic's director for research and the director of the new center. View Related  The Clinical Research Training Program provides a formal education in all aspects of clinical research, including grant-writing, legal and ethical issues, statistics, epidemiology and study design and protocols. "I realized how exciting research can be, and how exciting it is to advance the science." Jon Ebbert, M.D. View Related  The investigators found that anesthesia administered by direct infiltration of the prostate apex and the surrounding rectal tissues may provide better pain control during a prostate biopsy than other anesthetic methods. "The prostate biopsy likely will never be a completely painless procedure, but it should be tolerable," says Dr. Ashley. "Patients should request that anesthetic be used at the time of a biopsy, and pain control should be the standard of care in a urologist's office. It does not take much time, and patients do benefit from this simple procedure to make the biopsy more tolerable. Patients should also be aware that different prostate locations biopsied are associated with more pain, and this may never be completely overcome by anesthetic. However, a complete and thorough sampling of the prostate gland is necessary to give the most accurate diagnosis to the patient." View Related  "This collaboration will enable us to work with the Indian Health Service to address health care-related needs specific to Native Americans, ranging from developing research initiatives to address unique problems, to finding ways to improve access to medi View Related In helping young investigators, Mayo Clinic again is connecting all the dots -- leading back to the same point, the same mission, ongoing and yet unchanged for over a century: the needs of the patient come first. New, young investigators are critical to biomedical research. Their fresh ideas, innovativeness, and enthusiasm are necessary for scientific progress. Yet the steps from a junior research position toward a self-sufficient laboratory can be difficult. Mayo Clinic is dedicated to fostering future, investigators. Here we look at two of them and what Mayo is doing to help. View Related  Publication: Cancer -- June 15, 2006 The current results confirmed that there were changes in the prevalence of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. A chronological change in pathologic grading classification is suggested by evolving prognostic implications, which must be accounted for when comparing outcomes from different eras. View Related   Robert B. Diasio, M.D., has been appointed Mayo Clinic Cancer Center Director, succeeding Franklyn Prendergast, M.D., Ph.D. Dr. Diasio, who will be based at Mayo Clinic in Rochester, will also direct cancer center activities at Mayo Clinic in Arizona and Mayo Clinic in Jacksonville, Fla. View Related State and regional cancer survivors, their families and friends will come together to celebrate life during the upcoming 19th annual National Cancer Survivors Day Celebration, Sunday, June 4, 2006. "This celebration of life is for everyone," says Janine Kokal, Mayo Clinic nurse educator and local planning committee chair. "Whether you're a cancer survivor, a family member, a friend or a medical professional, National Cancer Survivors Day provides an opportunity for cancer survivors to connect with other survivors, and reunite with medical staff and families they've met along the way." View Related  Medical Edge Newspaper First, a cancer diagnosis. Then, worries about possible side effects from the treatment -- the nausea and vomiting you've heard about from others who have been treated for cancer. This article explores some of the options available for dealing with the side effects of treatment. View Related The first radiation therapy and respiratory care baccalaureate classes of Mayo School of Health Sciences and the University of Minnesota will be conferred on Friday, May 12, 2006, at Mayo Clinic. View Related  The invention of a novel imaging biotechnology called vibro-acoustography was reported in 1998, a fruit that matured from a mind dedicated to a deeper understanding of the mathematical and physical concepts that produce clear images of internal anatomy. James Greenleaf, Ph.D., a Mayo Clinic scientist and director of the Ultrasound Research Laboratory, is praised by the scientific community as one of the most creative scientists in ultrasonic biomedical imaging science. This article explores his contributions—novel ultrasound treatments, and biotechnology that produces clear images, some in 3D, of tiny structures deep within the body. View Related Now that this signal has been identified, new strategies can be generated for enhancing the ability of the immune system to kill tumor cells in patients with cancer. "Because NK cells can communicate different messages -- one that serves health by clearing tumors and viruses and one that serves disease by blocking the response to cancer -- understanding which signals result in effective tumor clearance is a high priority for those of us fighting cancer," explains Paul Leibson, M.D., Ph.D., the Mayo Clinic immunologist and pediatrician who led the study. View Abstract Mayo Clinic researchers have discovered clues about new molecular partnerships involving a key protein that naturally guards against cancer because it promotes repair of damaged DNA. Research shows that loss of p53 is directly related to cancer. People born without enough p53 function get spontaneous cancers. In about half of all cancers, the two genes that give the instructions for making p53 (each person gets one gene from each parent) are missing or shut off. This suggests that loss of p53 function is a common event in the origin of many different kinds of cancer. Therefore, an appealing research strategy is to devise ways to restore or protect p53 function. Discovering all the ways p53 gets turned on is an important first step toward doing that. View Abstract  Medical Edge Television Doctors are using robots for many operations including prostate cancer surgery. Learn the latest on how this advance in technology is helping some patients get better faster. Read Script Mayo Clinic researchers have uncovered a new cellular secret that may explain how certain cancers move and spread -- a feature of cancers that makes treatment especially difficult. "These findings have broad implications toward the general understanding of how specific processes in the wave may affect such things as cell growth, cell movement and metastasis," explains Mark McNiven, Ph.D., the lead researcher on the Mayo Clinic team. "Our work provides new insights into a novel mechanism by which cells can internalize growth factor information. Understanding this process is the first step toward one day halting it, preventing it or reversing it therapeutically." View Related  Identifying alterations in DNA methylation may also be useful in determining cancer progression Researchers at Mayo Clinic have narrowed the search for effective prostate cancer biomarkers (genetic variations that point to a specific disease or condition), identifying changes in the expression of genes of the whole genome closely correlated to prostate cancer development and progression. They also showed that DNA hypermethylation (DNA modification without changing sequence) plays a significant role in these processes. Results of their study were published in the Feb. 15, 2006, issue of Clinical Cancer Research. View Abstract  Mayo Clinic broke ground this morning for a new building to house advanced imaging research. Mayo received a gift of $7 million from The Opus Group to support construction of the facility. "Much of medicine in the future will depend heavily on noninvasive imaging techniques," says Denis Cortese, M.D., CEO of Mayo Clinic. "We are grateful for this generous gift from Opus, which will help us expand both our diagnostic and treatment capabilities through the findings of this research. Applying basic science research findings to patient care is what we do best, and we look for this activity to keep Mayo Clinic on the cutting edge of imaging." View Related  Medical Edge Newspaper DEAR MAYO CLINIC: I am a 75-year-old man in excellent health and still sexually active. After a minimally elevated prostate-specific antigen test, one of six needle biopsies showed prostate cancer. My doctor says to do nothing because my quality of life would be better. This doesn't seem right. What should I do? -- Seattle View Related In terms of a medical diagnosis, nothing is more devastating than hearing the "C" word - cancer. But now, ASU and Mayo Clinic are hoping that five different C's will become the best arsenal against the big C. The organizations have teamed up to introduce a new research entity called MAC5. MAC5 is short for the Mayo Clinic - ASU Center for Cancer-related Convergence, Cooperation and Collaboration. View Related         Publication: Journal of Clinical Oncology -- June 15, 2004 North Central Cancer Treatment Group with National Cancer Institute of Canada View Related  |
Legal restrictions and terms of use applicable to this site
Use of this site signifies your agreement to the terms of use
Copyright © 2008 Mayo Foundation for Medical Education and Research.